Lmap-05 bevacizumab and gamma knife radiosurgery in the treatment of first-recurrence glioblastoma

Abstract Glioblastoma is the most common central nervous system malignancy in adults and remains a uniformly fatal disease despite two decades of developments in surgical management, radiation treatment, chemotherapy, and immunotherapy. There is currently no established standard of care for patients with recurrent glioblastoma following failure of initial Stupp protocol management. In this retrospective cohort study, we set out to determine if the use of bevacizumab and/or Gamma Knife radiosurgery in patients with recurrent disease could have an effect on prolonging progression-free survival (PFS) or overall survival (OS). Patients in the combined treatment group demonstrated longer post-recurrence mean PFS (9.1 ± 6.0 months) and OS (13.5 ± 8.6 months) compared to glioblastoma patients previously reported in the literature, and showed improvements in total OS (p=0.021), total PFS (p=0.057), post-recurrence PFS (p=0.034), and post-recurrence OS (p=0.017) compared to patients who received standalone bevacizumab or Gamma Knife treatment. This study demonstrates that the combined use of an antiangiogenic agent with stereotactic radiosurgery can have significant effects on improving patient survival in recurrent glioblastoma.